Search results for " Obstructive."

showing 10 items of 477 documents

Chronic renal failure: a neglected comorbidity of COPD

2009

BACKGROUND: To the best of our knowledge, the association between COPD and chronic renal failure (CRF) has never been assessed. Lean mass is frequently reduced in COPD, and the glomerular filtration rate (GFR) might be depressed in spite of normal serum creatinine (concealed CRF). We investigated the prevalence and correlates of both concealed and overt CRF in elderly patients with COPD. METHODS: We evaluated 356 consecutive elderly outpatients with COPD enrolled in the Extrapulmonary Consequences of COPD in the Elderly Study and 290 age-matched outpatients free from COPD. The GFR was estimated using the Modification of Diet in Renal Disease Study Group equation. Patients were categorized a…

Aged 80 and overMaleComorbidityMiddle AgedSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveCOPD ElderlyCase-Control StudiesCreatininePrevalenceHumansKidney Failure ChronicRegression AnalysisFemaleAgedGlomerular Filtration Rate
researchProduct

Difference in Mortality Risk in Elderly People with Bronchial Obstruction Diagnosed Using a Fixed Cutoff or the Lower Limit of Normal of the FEV1/FVC…

2017

Background: Whether a fixed cutoff or the lower limit of normal of the FEV1/FVC ratio should be used to diagnose bronchial obstruction is still a matter of debate. This issue is particularly important for elderly people. Objectives: We used equations applicable up to 90 years of age to evaluate the mortality of elderly people diagnosed with bronchial obstruction using either a fixed cutoff of 0.7 or the lower limit of normal (LLN). Methods: Participants in the SaRA (Salute Respiratoria nell'Anziano, Italian for "Respiratory Health in the Elderly") study were grouped as follows: FEV1/FVC ≥0.7 and ≥ LLN (n = 535: F-/L-), FEV1/FVC <0.7 but ≥ LLN (n = 118: F+/L-), and FEV1/FVC <0.7 and < LLN (n…

Aged 80 and overMalePulmonary and Respiratory MedicineVital CapacityBronchial obstructionSettore MED/10 - Malattie Dell'Apparato RespiratorioRisk AssessmentLower limit of normalAlgorithmFixed cutoffElderlyItalyForced Expiratory VolumeHumansFemaleLung Diseases ObstructiveAlgorithmsAgedHuman
researchProduct

Effects of chronic airway disease on health status of geriatric patients.

2004

Background and aims: The impact of chronic airway disease on the health status of elderly patients is only to some extent explained by indexes of airflow limitation. The present study was designed to assess to what extent: 1) asthma, chronic obstructive pulmonary disease (COPD) and chronic bronchitis with normal FEV1 (simple bronchitis) differ in their impact on health status; 2) health status depends upon non-respiratory factors. Methods: A total of 1601 outpatients over 65 - 198 with asthma, 228 with COPD, 91 with simple bronchitis, and 1084 with non-respiratory illnesses (control group) -were studied by collection of five health status indexes and multidimensional assessment. Discriminan…

AgingChronic bronchitismedicine.medical_specialtyHealth StatusSettore MED/10 - Malattie Dell'Apparato RespiratorioPulmonary Disease Chronic ObstructiveInternal medicinemedicineHealth Status IndicatorsHumansRespiratory functionBronchitisAsthmaAgedCOPDbusiness.industryAnthropometrymedicine.diseaseComorbidityAsthmarespiratory tract diseasesAirway diseaseChronic DiseasePhysical therapyBronchitisaging quality of life COPDGeriatrics and GerontologybusinessAlgorithmsAging clinical and experimental research
researchProduct

Integrated care pathways for airway diseases (AIRWAYS-ICPs)

2014

International audience; The objective of Integrated Care Pathways for Airway Diseases (AIRWAYS-ICPs) is to launch a collaboration to develop multi-sectoral care pathways for chronic respiratory diseases in European countries and regions. AIRWAYS-ICPs has strategic relevance to the European Union Health Strategy and will add value to existing public health knowledge by: 1) proposing a common framework of care pathways for chronic respiratory diseases, which will facilitate comparability and trans-national initiatives; 2) informing cost-effective policy development, strengthening in particular those on smoking and environmental exposure; 3) aiding risk stratification in chronic disease patien…

AgingSettore MED/10 - Malattie dell'Apparato RespiratorioInternational CooperationRespiratory SystemMedically Underserved AreaComorbidityDiseaseEarly interventionMedical and Health Sciences[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractPulmonary Disease Chronic Obstructive0302 clinical medicineDisease controlRisk FactorsChronic obstructive lung diseaseHealth care030212 general & internal medicineRhinitimedia_commonRhinitisEnvironmental exposureChild health care3. Good healthALLERGIC RHINITISEuropeCHRONIC RESPIRATORY-DISEASESPERFORMANCE PROGRAMAction planSIMULATIONAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease; Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health OrganizationSMOKINGHumanPulmonary and Respiratory Medicinemedicine.medical_specialtyChronic ObstructiveChronic respiratory tract diseaseDecision MakingGuidelines as TopicDIAGNOSISWorld Health OrganizationOBSTRUCTIVE PULMONARY-DISEASEPulmonary Disease03 medical and health sciencesQuality of life (healthcare)EUROPEAN-UNIONmedicineMANAGEMENTmedia_common.cataloged_instanceHumansEuropean UnionEuropean unionIntensive care medicinebusiness.industryPublic healthRisk Factorta3121Respiration DisorderEnvironmental exposureRespiration DisordersAsthmaIntegrated care030228 respiratory systemPhysical therapyQuality of LifeClinical MedicineAging; Asthma; Decision Making; Europe; European Union; Guidelines as Topic; Humans; International Cooperation; Medically Underserved Area; Pulmonary Disease Chronic Obstructive; Quality of Life; Respiration Disorders; Rhinitis; Risk Factors; World Health Organizationbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologySEVERE ASTHMA
researchProduct

Comorbidities of Lung Disease in the Elderly

2017

Comorbidities are common in elderly individuals with chronic respiratory diseases. They can affect disease manifestations and severity and can even impact management. Comorbidities can affect the treatment of the lung disease, particularly because of the interaction with the respiratory drugs. Thus, a multidimensional approach with multidisciplinary intervention is suggested for elderly respiratory patients, switching from a disease-oriented scheme to a dysfunction-oriented approach. Unfortunately, older individuals are often excluded from clinical trials because of advanced age and comorbidities. This article reviews the role of comorbidities in the management of respiratory diseases in th…

Agingmedicine.medical_specialtyRespiratory Tract DiseasesComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAffect (psychology)03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineHumansSenile lung030212 general & internal medicineRespiratory systemIdiopathic lung fibrosiIntensive care medicineRespiratory Tract DiseaseAgedAsthmabusiness.industryChronic obstructive pulmonary diseasefood and beveragesmedicine.diseaseComorbidityAsthmaPatient Care ManagementClinical trial030228 respiratory systemLung diseaseGeriatrics and GerontologybusinessHumanClinics in Geriatric Medicine
researchProduct

Mild to moderate chronic airways disease does not carry an excess risk of cognitive dysfunction

2003

Whether chronic obstructive pulmonary disease (COPD) carries a risk of cognitive dysfunction prior to the onset of arterial hypoxemia is not known. Our objective was to assess both the prevalence and main correlates of subclinical cognitive dysfunction in older patients with non-hypoxemic COPD.Home-dwelling non-demented subjects over 64 years of age consecutively attending 24 outpatient Departments of Respiratory Medicine or Geriatrics because of COPD (N = 233), asthma (N = 203), non-obstructive bronchitis (N = 92) or chronic non-respiratory and non-dementing diseases (controls, N = 1080) underwent a multidimensional assessment. Cognitive status was assessed by the Mini-Mental State Examina…

Agingmedicine.medical_specialtyVital capacityNeuropsychological TestsSeverity of Illness IndexPulmonary Disease Chronic ObstructiveRisk FactorsInternal medicineSeverity of illnessmedicineHumansRespiratory functionAgedAsthmaAged 80 and overGeriatricsCOPDbusiness.industrymedicine.diseaseMultivariate AnalysisPhysical therapyBronchitisGeriatric Depression ScaleGeriatrics and GerontologyCognition DisordersbusinessAging Clinical and Experimental Research
researchProduct

Why use long acting bronchodilators in chronic obstructive lung diseases? An extensive review on formoterol and salmeterol

2015

Abstract Long-acting β 2 -adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Although no specific indications concerning the choice of one molecule rather than another are provided by asthma and COPD guidelines, they present different pharmacological properties resulting in distinct clinical employment possibilities. In particular, salmeterol has a low intrinsic efficacy working as a partial receptor agonist, while formoterol is a full agonist with high intrinsic efficacy. From a clinical perspective, in the presence of low β 2 -adrenoceptors availability, like in inflamed airways, a full agonist can maintain its b…

AgonistChronic ObstructiveIntrinsic activitymedicine.drug_classSocio-culturaleLABASettore MED/10 - Malattie Dell'Apparato RespiratorioPharmacologyPartial agonistPulmonary DiseaseAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Internal MedicinePulmonary Disease Chronic Obstructiveimmune system diseasesFormoterol FumarateInternal MedicinemedicineHumansFormoterolSalmeterolSalmeterol XinafoateBronchodilator AgentAsthmaCOPDbusiness.industryChronic obstructive pulmonary diseaseMedicine (all)Asthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterolrespiratory systemmedicine.diseaseAsthmaBronchodilator Agentsrespiratory tract diseasesTreatment OutcomeAnesthesiaFormoterolOnset of actionSalmeterolbusinessAsthma; Chronic obstructive pulmonary disease; Formoterol; LABA; Salmeterol; Bronchodilator Agents; Formoterol Fumarate; Humans; Pulmonary Disease Chronic Obstructive; Salmeterol Xinafoate; Treatment Outcome; Internal MedicineHumanmedicine.drugEuropean Journal of Internal Medicine
researchProduct

Manifesto on small airway involvement and management in asthma and chronic obstructive pulmonary disease: an Interasma (Global Asthma Association - G…

2016

International audience; Evidence that enables us to identify, assess, and access the small airways in asthma and chronic obstructive pulmonary disease (COPD) has led INTERASMA (Global Asthma Association) and WAO to take a position on the role of the small airways in these diseases. Starting from an extensive literature review, both organizations developed, discussed, and approved the manifesto, which was subsequently approved and endorsed by the chairs of ARIA and GA2LEN. The manifesto describes the evidence gathered to date and defines and proposes issues on small airway involvement and management in asthma and COPD with the aim of challenging assumptions, fostering commitment, and bringin…

Allergic Rhinitislcsh:Immunologic diseases. AllergyPulmonary and Respiratory MedicineManifestomedicine.medical_specialtyAllergyChronic Obstructive Pulmonary DiseaseImmunologyMEDLINEDiseaseSettore MED/10 - Malattie Dell'Apparato Respiratoriosmall airways asthma aerosolBiochemistry03 medical and health sciences0302 clinical medicine[ SDV.MHEP ] Life Sciences [q-bio]/Human health and pathology/dk/atira/pure/subjectarea/asjc/2700/2723Position Article and GuidelinesmedicineImmunology and Allergy030212 general & internal medicinesmall airwayIntensive care medicineAsthmaCOPDLungbusiness.industryasthma airway inflammationOrganic Chemistrysmall airways asthma control aerosol1103 Clinical SciencesChronic Obstructive Pulmonary Disease Patientasthmarespiratory systemmedicine.diseaserespiratory tract diseasesmedicine.anatomical_structure030228 respiratory systemPhysical therapylcsh:RC581-607AirwaybusinesscontrolThe World Allergy Organization Journal
researchProduct

Relationship Between the Apolipoprotein E Genotype and LDL Particle Size in Patients With Obstructive Sleep Apnea.

2016

Obstructive sleep apnea (OSA) is associated with dyslipidemia and increased cardiovascular risk. We assessed the effects of apolipoprotein E ( APOE) genotype on low-density lipoprotein (LDL) and high-density lipoprotein (HDL) particle size and lipid subclasses (separated by gradient gel electrophoresis) in patients with OSA. Stable patients (n = 181) prospectively recruited underwent full polysomnography. Both LDL particle size and LDL I proportion were reduced from ∊3∊3 homozygotes to ∊2 carriers and to ∊4 carriers (analysis of variance: P = .024; P = .040, respectively); carriers of the ∊4 allele of the APOE genotype had significantly lower LDL particle size and LDL I proportion compared…

Apolipoprotein EAdultMalemedicine.medical_specialtyGenotypePolysomnographyApolipoprotein E4Statistics as TopicPolysomnography030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineInsulin resistanceApolipoproteins EInternal medicineGenotypemedicineHumansGenetic Predisposition to Disease030212 general & internal medicineProspective StudiesParticle SizeAgedSleep Apnea Obstructivemedicine.diagnostic_testbusiness.industryGenetic Carrier ScreeningMiddle Agedmedicine.diseaseObstructive sleep apneaLipoproteins LDLEndocrinologyCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleMetabolic syndromeCardiology and Cardiovascular MedicinebusinessDyslipidemiaLipoproteinAngiology
researchProduct

Outcome and attitudes toward home tracheostomy ventilation of consecutive patients: a 10-year experience.

2008

Summary Objectives To describe survival, predictors of long-term outcome and attitudes in patients treated at home by tracheostomy-intermittent positive-pressure ventilation (TIPPV) for respiratory failure during a 10-year period (1995–2004). Methods Seventy-seven consecutive patients were treated by TIPPV at home. Patients were divided into three groups: neuromuscular, pulmonary, and non-pulmonary patients. Effects of TIPPV on survival, factors influencing outcome after TIPPV, and attitudes of patients and caregivers regarding mechanical ventilation were studied. Results Forty-one patients (53%) were neuromuscular, 19 (25%) were affected by pulmonary diseases, and 17 (22%) by non-pulmonary…

Artificial ventilationPulmonary and Respiratory MedicineAdultMalemedicine.medical_specialtySurvivalHome Nursingmedicine.medical_treatmentRespiratory failureIntermittent Positive-Pressure VentilationPulmonary Disease Chronic ObstructiveTracheotomyTracheostomyInternal medicinemedicineCOPDHumansProspective StudiesProspective cohort studySurvival rateAgedMechanical ventilationAged 80 and overCOPDbusiness.industryTracheostomy mechanical ventilationRespiratory diseaseAmyotrophic Lateral SclerosisNeuromuscular DiseasesMiddle Agedmedicine.diseaseRespiration ArtificialSurgerySurvival RateCaregiversRespiratory failureFemaleALSbusinessRespiratory InsufficiencyAttitude to HealthRespiratory medicine
researchProduct